Molecular Container to Enhance Aqueous Solubility of Drugs
University of Maryland
posted on 08/18/2010
Researchers at the University of Maryland have discovered a new cucurbit[n]uril-type molecular container that binds to a variety of FDA approved agents in water. For example the new CB[n]-type container binds to Rocuronium which is a widely used anesthetic during surgery. By sequestering Rocuronium post-operatively by the application of the new CB[n]-type container, the recovery time of the patient is decreased.
Suggested Uses
- Solubility Enhancement for a variety of pharmaceutical agents and drugs
Advantages
- Containers can be produced in scalable quantities at minimal cost
- Promising results from toxicity tests on human cell lines
Detailed Description
Researchers at the University of Maryland have discovered a new cucurbit[n]uril-type molecular container that binds to a variety of FDA approved agents in water. For example the new CB[n]-type container binds to Rocuronium which is a widely used anesthetic during surgery. By sequestering Rocuronium post-operatively by the application of the new CB[n]-type container, the recovery time of the patient is decreased. The excellent aqueous solubility (≥ 100 mM) of this new CB[n]-type container makes it ideal for intravenous administration. The new CB[n]-type container has also been successfully tested for enhancing the aqueous solubility of a multitude of FDA approved pharmaceuticals including anti-cancer, anti-arrhythmic, anti-clotting and anti-histamine drugs and agents. Toxicity studies in human cell lines establish that the new CB[n]-type container is bio-compatible (e.g. non-toxic). A scalable, efficient, and cost effective synthetic route to this compound has also been developed by the same researchers.
File Number: LS-2010-039
Web site: http://otc.umd.edu
This innovation currently is not available for online licensing. Please contact the case manager at University of Maryland for more information.
Find more innovations
